PL3394248T3 - Kompozycja komórek dendrytycznych - Google Patents

Kompozycja komórek dendrytycznych

Info

Publication number
PL3394248T3
PL3394248T3 PL16825765T PL16825765T PL3394248T3 PL 3394248 T3 PL3394248 T3 PL 3394248T3 PL 16825765 T PL16825765 T PL 16825765T PL 16825765 T PL16825765 T PL 16825765T PL 3394248 T3 PL3394248 T3 PL 3394248T3
Authority
PL
Poland
Prior art keywords
composition
dendritic cells
dendritic
cells
Prior art date
Application number
PL16825765T
Other languages
English (en)
Inventor
Slavoljub Milosevic
Christian ELLINGER
Carina WEHNER
Dolores Schendel
Original Assignee
Medigene Immunotherapies Gmbh
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Immunotherapies Gmbh, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) filed Critical Medigene Immunotherapies Gmbh
Publication of PL3394248T3 publication Critical patent/PL3394248T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
PL16825765T 2015-12-23 2016-12-22 Kompozycja komórek dendrytycznych PL3394248T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15202329 2015-12-23
EP16190399 2016-09-23
PCT/EP2016/082445 WO2017109110A1 (en) 2015-12-23 2016-12-22 Dendritic cell composition
EP16825765.7A EP3394248B1 (en) 2015-12-23 2016-12-22 Dendritic cell composition

Publications (1)

Publication Number Publication Date
PL3394248T3 true PL3394248T3 (pl) 2021-09-13

Family

ID=57794260

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16825765T PL3394248T3 (pl) 2015-12-23 2016-12-22 Kompozycja komórek dendrytycznych
PL16825764T PL3394247T3 (pl) 2015-12-23 2016-12-22 Nowy sposób wytwarzania tcr swoistych wobec antygenu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16825764T PL3394247T3 (pl) 2015-12-23 2016-12-22 Nowy sposób wytwarzania tcr swoistych wobec antygenu

Country Status (17)

Country Link
US (2) US11155589B2 (pl)
EP (4) EP3394248B1 (pl)
JP (3) JP6676759B2 (pl)
KR (4) KR102319839B1 (pl)
CN (2) CN108603171A (pl)
AU (2) AU2016374874B2 (pl)
BR (2) BR112018012694A2 (pl)
CA (2) CA3009542C (pl)
DK (2) DK3394247T3 (pl)
EA (2) EA201891460A1 (pl)
ES (2) ES2863733T3 (pl)
HU (1) HUE053674T2 (pl)
MX (2) MX2018007842A (pl)
PH (2) PH12018501336A1 (pl)
PL (2) PL3394248T3 (pl)
TW (2) TWI772282B (pl)
WO (2) WO2017109110A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987871A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
JP6568239B2 (ja) 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
WO2017109110A1 (en) 2015-12-23 2017-06-29 Medigene Immunotherapies Gmbh Dendritic cell composition
MA51043A (fr) * 2017-12-04 2020-10-14 Us Health Récepteurs de lymphocytes t, limités à l'antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée
US11015402B2 (en) 2018-04-27 2021-05-25 Canrig Robotic Technologies As System and method for conducting subterranean operations
US10808465B2 (en) * 2018-04-27 2020-10-20 Canrig Robotic Technologies As System and method for conducting subterranean operations
AU2019289973B2 (en) * 2018-06-21 2025-09-11 Universiteit Gent Method for the in vitro differentiation and maturation of dendritic cells for therapeutic use
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
WO2020247510A1 (en) * 2019-06-03 2020-12-10 The Scripps Research Institute A chemoenzymatic method for the detection of cell-cell proximity interaction and isolation of tumor-specific antigen reactive t cells for immune therapy
KR20210090561A (ko) * 2020-01-10 2021-07-20 주식회사 엘지화학 Mhc 및 종양 항원을 동시 발현하는 항원제시세포를 포함하는 조성물 및 이를 이용한 암 치료
CN112133372B (zh) * 2020-08-18 2022-06-03 北京臻知医学科技有限责任公司 抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
KR102751115B1 (ko) * 2020-10-20 2025-01-09 연세대학교 산학협력단 단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
US20240002795A1 (en) * 2020-11-24 2024-01-04 Providence Health & Services - Oregon T cell receptors specific for a mutant form of the ret oncogene and uses thereof
WO2023060163A2 (en) * 2021-10-06 2023-04-13 Board Of Regents, The University Of Texas System Shp1 modified dendritic cells and extracellular vesicles derived therefrom and associated methods
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH05504621A (ja) 1989-11-15 1993-07-15 ナショナル・ジューイッシュ・センター・フォア・イミュノロジー・アンド・レスピラトリー・メディスン ヒトｔ細胞表面抗原の定量法
KR930701620A (ko) 1990-08-09 1993-06-12 프레드릭 에이. 란길레 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
JPH05505112A (ja) 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
US5480895A (en) 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69321962T2 (de) 1992-08-21 1999-07-01 Biogen Inc Von tat abgeleitete transportpolypeptide
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19625191A1 (de) 1996-06-24 1998-01-02 Boehringer Mannheim Gmbh Nierenkarzinom-spezifische T-Zellen
US6284879B1 (en) * 1998-04-16 2001-09-04 The General Hospital Corporation Transport associated protein splice variants
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
US20050112141A1 (en) 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
AU2001232204A1 (en) 2000-02-22 2001-09-03 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
CA2405363A1 (en) * 2000-04-28 2001-11-08 Ctl Immunotherapies Corp. Epitope synchronization in antigen presenting cells
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
FR2822846B1 (fr) 2001-04-03 2004-01-23 Technopharm Procede de preparation et de selection d'anticorps
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
PL2327763T3 (pl) 2005-08-05 2018-08-31 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generowanie komórek T specyficznych względem antygenu
JP2007097580A (ja) 2005-09-06 2007-04-19 Shizuoka Prefecture Ｔ細胞レセプターβ鎖遺伝子
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US20100247430A1 (en) * 2007-08-30 2010-09-30 Andrew Chan Methods and Compositions for Modulating T Cells
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US8394778B1 (en) * 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
WO2011053789A2 (en) * 2009-10-30 2011-05-05 James Cameron Oliver Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2011107409A1 (en) 2010-03-02 2011-09-09 F. Hoffmann-La Roche Ag Expression vector
CN102719399A (zh) * 2012-04-28 2012-10-10 北京爱根生物科技有限公司 自体特异性t细胞的体外扩增方法及所制备的t细胞体系、体系的药物应用和组分监测方法
EP3808361A1 (en) 2012-06-15 2021-04-21 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
BR112016021004A2 (pt) 2014-03-14 2018-01-23 Immunocore Limited biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
WO2016057986A1 (en) 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
JP6568239B2 (ja) 2015-06-01 2019-08-28 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体ライブラリ
CA2987871A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
MX2017015619A (es) 2015-06-01 2018-08-15 Medigene Immunotherapies Gmbh Anticuerpos especificos de receptor de celulas t.
WO2017109110A1 (en) 2015-12-23 2017-06-29 Medigene Immunotherapies Gmbh Dendritic cell composition

Also Published As

Publication number Publication date
HUE053674T2 (hu) 2021-07-28
MX2018007841A (es) 2018-11-09
JP2018537999A (ja) 2018-12-27
NZ741954A (en) 2020-04-24
EP3889253A1 (en) 2021-10-06
KR20180089446A (ko) 2018-08-08
PH12018501335A1 (en) 2019-02-18
CN108473960A (zh) 2018-08-31
US10882891B2 (en) 2021-01-05
DK3394247T3 (da) 2021-04-12
JP2020114222A (ja) 2020-07-30
ES2863733T3 (es) 2021-10-11
TW201736595A (zh) 2017-10-16
BR112018012826A2 (pt) 2018-12-04
AU2016374874B2 (en) 2020-12-03
EP3394247A1 (en) 2018-10-31
US20190002515A1 (en) 2019-01-03
KR102319839B1 (ko) 2021-11-01
EA201891459A1 (ru) 2018-11-30
TWI752930B (zh) 2022-01-21
AU2016374873A1 (en) 2018-05-17
EP3394248A1 (en) 2018-10-31
PH12018501336A1 (en) 2019-02-18
KR20200100858A (ko) 2020-08-26
EP3394248B1 (en) 2021-02-10
KR20180093954A (ko) 2018-08-22
EP3394247B1 (en) 2021-02-10
WO2017109110A1 (en) 2017-06-29
TWI772282B (zh) 2022-08-01
JP6697562B2 (ja) 2020-05-20
AU2016374874A1 (en) 2018-05-17
CA3009564A1 (en) 2017-06-29
WO2017109109A1 (en) 2017-06-29
CA3009564C (en) 2023-08-29
JP6676759B2 (ja) 2020-04-08
CA3009542C (en) 2023-08-29
CN108603171A (zh) 2018-09-28
EA201891460A1 (ru) 2018-12-28
US11155589B2 (en) 2021-10-26
CA3009542A1 (en) 2017-06-29
BR112018012694A2 (pt) 2018-12-04
AU2016374873B2 (en) 2020-12-24
PL3394247T3 (pl) 2021-08-23
NZ741955A (en) 2020-04-24
MX2018007842A (es) 2018-11-09
KR20200085362A (ko) 2020-07-14
EP3901254A1 (en) 2021-10-27
DK3394248T3 (da) 2021-04-19
TW201736594A (zh) 2017-10-16
US20190000949A1 (en) 2019-01-03
ES2865484T3 (es) 2021-10-15
JP2018538001A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
PL3394248T3 (pl) Kompozycja komórek dendrytycznych
DK3361870T3 (da) Fungicidsammensætninger
PT3355990T (pt) Compostos semifluorados e as suas composições
KR20180084891A (ko) 구조 조성물 및 방법
HUE043599T2 (hu) Nem-vizes elektrolit kompozíciók
DK3130649T3 (da) Haloolefin-baseret sammensætning
DK3215173T3 (da) Glycopeptidsammensætninger
DK3892302T3 (da) Sammensætninger indeholdende ibrutinib
EP3339331A4 (en) COMPOSITION
EP3398996A4 (en) COMPOSITION
FR3024363B1 (fr) Composition thermogelifiable
DK3254325T3 (da) Elektrolytdannelsesfremgangsmåde
DK3254326T3 (da) Elektrolytdannelsesfremgangsmåde
DK3250182T3 (da) Dispergible sammensætninger
DK3334726T3 (da) Plinabulinsammensætninger
DK3157504T3 (da) Stamcellestimulerende sammensætninger
DK3283210T3 (da) Fremgangsmåde
CL2017000639A1 (es) Composición
EP3395887C0 (en) FLUOROR RUBBER COMPOSITION
DK3322295T3 (da) Sammensætning
IL254502B (en) Solid forms of menaquinols
DK3331498T3 (da) Nasalsammensætning
DK3316857T3 (da) Multifasiske sammensætninger
DK3393254T3 (da) Sammensætning
LT3173071T (lt) Maropitanto kompozicija